RadNet (NASDAQ:RDNT) Rating Lowered to “Hold” at Zacks Research

RadNet (NASDAQ:RDNT) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

Several other research firms also recently weighed in on RDNT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of RadNet in a report on Wednesday, November 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of RadNet in a research report on Tuesday, September 22nd. Truist Financial raised their target price on shares of RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Barclays boosted their price target on shares of RadNet from $65.00 to $79.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Finally, Jefferies Financial Group restated a “buy” rating on shares of RadNet in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $90.43.

RadNet Stock Down 0.6%

Shares of RadNet stock opened at $77.94 on Monday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.49 and a quick ratio of 1.48. RadNet has a 1-year low of $50.82 and a 1-year high of $85.84. The business’s fifty day moving average price is $72.69 and its two-hundred day moving average price is $65.45. The company has a market capitalization of $6.13 billion, a P/E ratio of -268.76 and a beta of 1.42.

RadNet (NASDAQ:RDNT) last released its quarterly earnings results on Sunday, November 8th. The medical research company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.08. The company had revenue of $638.26 million during the quarter, compared to analysts’ expectations of $639.97 million. RadNet had a positive return on equity of 3.14% and a negative net margin of 0.94%. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 earnings per share. As a group, research analysts forecast that RadNet will post 0.49 EPS for the current year.

Hedge Funds Weigh In On RadNet

Several hedge funds have recently modified their holdings of RDNT. BlackRock Inc. bought a new stake in shares of RadNet in the 2nd quarter worth $675,768,000. JB Capital Partners LP bought a new position in RadNet during the second quarter valued at about $87,821,842. Dimensional Fund Advisors LP boosted its stake in RadNet by 1.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,379,003 shares of the medical research company’s stock valued at $77,074,000 after buying an additional 19,188 shares in the last quarter. Bamco Inc. NY bought a new position in RadNet during the second quarter valued at about $77,765,000. Finally, Van Berkom & Associates Inc. grew its holdings in RadNet by 24.9% during the first quarter. Van Berkom & Associates Inc. now owns 1,028,586 shares of the medical research company’s stock worth $57,488,000 after acquiring an additional 204,858 shares during the period. 77.90% of the stock is currently owned by institutional investors and hedge funds.

More RadNet News

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: RadNet reported third-quarter EPS of $0.30, above the $0.22 consensus, while revenue rose 22.1% year over year. It also raised its 2026 revenue outlook to $2.5 billion–$2.6 billion; reports described this as the third consecutive quarterly guidance increase. RadNet Q3 earnings and outlook
• Positive Sentiment: The planned ONRAD acquisition would give RadNet direct access to more than 225 hospitals and expand its inpatient reach. One analysis said ONRAD’s EBITDA margins above 30% could make the deal margin-accretive. Separately, Digital Health’s year-to-date contract value reached $108 million. RadNet: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: KeyCorp raised its price target to $95 from $92 and maintained an Overweight rating, signaling analyst confidence in further upside. KeyCorp stock recommendations
• Neutral Sentiment: A short-interest report stated that short interest totaled zero shares as of November 10, despite describing it as a large increase. The reported figure and description appear inconsistent, so this is not a clear trading signal.
• Negative Sentiment: Quarterly revenue of $638.26 million came in slightly below the $639.97 million analyst estimate, and RadNet reported a negative net margin. These factors may have offset some of the otherwise strong results.

RadNet Company Profile

RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.